MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. To confirm the efficacy and safety of MD1003 in progressive MS in a double-blind, placebo-controlled study. Patients (n = 154) with a baseline Expanded Disability Sta...

Full description

Saved in:

Bibliographic Details
Published in:	Multiple sclerosis Vol. 22; no. 13; p. 1719
Main Authors:	Tourbah, Ayman, Lebrun-Frenay, Christine, Edan, Gilles, Clanet, Michel, Papeix, Caroline, Vukusic, Sandra, De Sèze, Jerome, Debouverie, Marc, Gout, Olivier, Clavelou, Pierre, Defer, Gilles, Laplaud, David-Axel, Moreau, Thibault, Labauge, Pierre, Brochet, Bruno, Sedel, Frédéric, Pelletier, Jean
Format:	Journal Article
Language:	English
Published:	England 01.11.2016
Subjects:	Adult Biotin - administration & dosage Biotin - adverse effects Biotin - pharmacology Disease Progression Double-Blind Method Female Humans Male Middle Aged Multiple Sclerosis, Chronic Progressive - drug therapy Outcome Assessment, Health Care Vitamin B Complex - administration & dosage Vitamin B Complex - adverse effects Vitamin B Complex - pharmacology clinical trial Multiple sclerosis MD1003 primary progressive multiple sclerosis disability progression high-dose biotin secondary progressive multiple sclerosis
ISSN:	1477-0970, 1477-0970
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!